VentriPoint Diagnostics (TSE:VPT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ventripoint Diagnostics has received Health Canada’s approval for its AI-powered VMS+4.0 heart-scanning technology, promising to enhance user experience and efficiency for cardiac clinicians. The device, which is compatible with magnet-free sensors, offers a significant advantage for patients unable to undergo MRI due to intracardiac devices. VMS+4.0 will serve as a premium offering alongside the already established VMS+3.0 product in the Canadian market.
For further insights into TSE:VPT stock, check out TipRanks’ Stock Analysis page.